Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immutep ADS Representing 10 Ord Shs IMMP

Healthcare Biotechnology
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.


NDAQ:IMMP - Post by User

Immutep ADS Representing 10 Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson Jul 12, 2024 11:02am
41 Views
Post# 36130147

QS, SWN, IMMP, KEY, NCLH showing five-day upward surge

QS, SWN, IMMP, KEY, NCLH showing five-day upward surge
Breaking News: $IMMP QS, SWN, IMMP, KEY, NCLH showing five-day upward surge2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...IMMP - QS, SWN, IMMP, KEY, NCLH showing five-day upward surge

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities